Alkermes News

Analysts Are Bullish on These Healthcare Stocks: Atricure (ATRC), Alkermes (ALKS)

TipRanksApr 29 07:18 ET

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Ocular Therapeutix (OCUL)

TipRanksApr 19 06:30 ET

Alkermes Analyst Ratings

BenzingaApr 19 06:15 ET

Analysts Conflicted on These Healthcare Names: Enliven Therapeutics (ELVN), Alkermes (ALKS) and Apellis Pharmaceuticals (APLS)

TipRanksApr 18 01:10 ET

Analysts Offer Insights on Healthcare Companies: Catalent (CTLT), Vertex Pharmaceuticals (VRTX) and Alkermes (ALKS)

TipRanksApr 12 01:41 ET

Hold Rating on Alkermes Amid Promising ALKS 2680 Data and Regulatory Challenges

TipRanksApr 12 01:38 ET

Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), DocGo (DCGO) and Alkermes (ALKS)

TipRanksApr 10 07:20 ET

Balanced Hold Rating for Alkermes Amidst Promising Data and Development Risks

TipRanksApr 10 06:26 ET

Buy Rating Affirmed for Alkermes on Promising ALKS 2680 Clinical Trial Results and Growth Potential

TipRanksApr 9 20:55 ET

Alkermes's ALKS-2680 Shows Promising Efficacy in NT2, Enhancing Market Outlook and Supporting a Buy Rating

TipRanksApr 9 12:15 ET

Alkermes Analyst Ratings

BenzingaApr 9 12:06 ET

Analysts Conflicted on These Healthcare Names: Chemed (CHE) and Alkermes (ALKS)

TipRanksApr 9 11:50 ET

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS), LifeMD (LFMD) and Apyx Medical (APYX)

TipRanksApr 9 09:10 ET

Alkermes Analyst Ratings

BenzingaApr 1 10:27 ET

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS), Opko Health (OPK) and Leafly Holdings, Inc. (LFLY)

TipRanksApr 1 07:10 ET

Baird Initiates Alkermes With Outperform Rating, Price Target Is $37

MT NewswiresMar 19 08:59 ET

Alkermes Analyst Ratings

BenzingaMar 19 04:49 ET

Analysts Conflicted on These Healthcare Names: Cencora (COR), Alkermes (ALKS) and Intellia Therapeutics (NTLA)

TipRanksFeb 26 07:10 ET

Alkermes Downgraded at UBS as Stock Nears 52-week High

Seeking AlphaFeb 20 12:32 ET

UBS Cuts Alkermes Rating to Sell Amid Concerns Over Pipeline Spread

InvestingFeb 20 07:16 ET